| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/16/2007 | CA2641055A1 Heterobicyclic amide derivatives |
| 08/16/2007 | CA2641043A1 Polymeric implant and a process for obtaining a polymeric implant |
| 08/16/2007 | CA2640665A1 Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives |
| 08/16/2007 | CA2640662A1 Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating cetp-mediated disorders |
| 08/16/2007 | CA2640652A1 Novel coumarin derivative having antitumor activity |
| 08/16/2007 | CA2640476A1 Compounds and methods for modulating fx-receptors |
| 08/16/2007 | CA2640472A1 Dipyridamole extended-release formulations and process for preparing same |
| 08/16/2007 | CA2640470A1 Non-natural amino acid derivatives |
| 08/16/2007 | CA2640229A1 Sulfonamide derivatives to treat infection with hepatitis c virus |
| 08/16/2007 | CA2640094A1 Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| 08/16/2007 | CA2640013A1 Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| 08/16/2007 | CA2639939A1 Compounds for the treatment of metabolic disorders |
| 08/16/2007 | CA2639924A1 Inhibitors of e1 activating enzymes |
| 08/16/2007 | CA2638816A1 Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus |
| 08/16/2007 | CA2638026A1 Bladder cancer treatment by using e09 and propylene glycol |
| 08/16/2007 | CA2637817A1 Vitamin d analog - nel, methods and uses thereof |
| 08/16/2007 | CA2637815A1 Crystalline forms of ciclesonide |
| 08/16/2007 | CA2637792A1 Combination of organic compounds |
| 08/16/2007 | CA2637771A1 Anthranilamide/2-amino-heteroarene carboxamide derivatives |
| 08/16/2007 | CA2637768A1 Benzamide and heteroarene derivatives |
| 08/16/2007 | CA2637709A1 Hydroxylamines and derivatives as anti-angiogenic agents |
| 08/16/2007 | CA2637302A1 Vitamin d analog-rak, methods and uses thereof |
| 08/16/2007 | CA2637292A1 Use of 2-imidazoles for the treatment of cns disorders |
| 08/16/2007 | CA2637225A1 Compounds and compositions as protein kinase inhibitors |
| 08/16/2007 | CA2637204A1 Substituted quinolones iii |
| 08/16/2007 | CA2637158A1 Oxazolidinones containing oxindoles as antibacterial agents |
| 08/16/2007 | CA2637047A1 Novel neurological function of mpkci |
| 08/16/2007 | CA2636736A1 Preparation of 7-alkenyl-3 quinolinecarbonitriles via a palladium mediated coupling reaction |
| 08/16/2007 | CA2635841A1 Stable pharmaceutical formulations of montelukast sodium |
| 08/16/2007 | CA2635834A1 Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation |
| 08/16/2007 | CA2635797A1 Stable formulations, and methods of their preparation and use |
| 08/16/2007 | CA2635138A1 Piperidine derivatives as cxcr3 receptor antagonists |
| 08/16/2007 | CA2635137A1 Piperidine derivatives as cxcr3 receptor antagonists |
| 08/16/2007 | CA2634419A1 Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| 08/16/2007 | CA2633725A1 Method of treating pediatric patients with corticosteroids |
| 08/16/2007 | CA2629336A1 [4-(benzo[b]thiophen-2-yl)pyrimidin-2yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases |
| 08/16/2007 | CA2627900A1 Compounds and compositions as lxr modulators |
| 08/16/2007 | CA2623729A1 Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic |
| 08/15/2007 | EP1818406A1 Gene construction, vector and dna vaccine for the vaccination of aquatic animals |
| 08/15/2007 | EP1818342A2 Purified primate CTLA-8 antigens and related reagents |
| 08/15/2007 | EP1818338A1 Process for the preparation of norelgestromin |
| 08/15/2007 | EP1818334A1 Anti-trypanosomiasis agent |
| 08/15/2007 | EP1818333A1 Vanilloid receptor ligands and their use in treatments |
| 08/15/2007 | EP1818330A1 Substituted proline amides, preparation and use as medicaments thereof |
| 08/15/2007 | EP1818329A1 (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2methyl-1,4homopiperazine hydrochloride dihydrate |
| 08/15/2007 | EP1818328A1 Chromatographic method for the isolation and purification of taxane derivatives |
| 08/15/2007 | EP1818326A1 Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds |
| 08/15/2007 | EP1818325A2 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| 08/15/2007 | EP1818063A1 Medicine for treatment of disease caused by hyperstimulatory cytotoxicity and therapeutic method |
| 08/15/2007 | EP1818062A1 An anti HSP90 antibody |
| 08/15/2007 | EP1818059A1 Preventive or therapeutic agent for glaucoma |
| 08/15/2007 | EP1818058A2 Treatment of mmp-mediated dermatological diseases with pemirolast |
| 08/15/2007 | EP1818057A1 Stable pharmaceutical formulations of montelukast sodium |
| 08/15/2007 | EP1818056A1 Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 08/15/2007 | EP1818055A1 Athletic ability enhancing composition |
| 08/15/2007 | EP1818054A1 Use of a gadolinium chelate for labeling cells |
| 08/15/2007 | EP1818053A1 Preventive/remedy for allergic diseases |
| 08/15/2007 | EP1818052A1 Use of formoterol in the prophylactic and/or therapeutic treatment of muscle wasting and/or cachectic syndrome which are associated with catabolic conditions of certain diseases, such as cancer, aids, infections, diabetes and others |
| 08/15/2007 | EP1818051A1 Microgranules of morphine sulphate, preparation method and composition containing them |
| 08/15/2007 | EP1818050A1 Stable pharmaceutical compositions comprising a HMG-CoA reductase inhibitor |
| 08/15/2007 | EP1818049A2 Stabilized Atorvastatin |
| 08/15/2007 | EP1818047A2 Oral administration form for difficulty soluble basic active ingredients |
| 08/15/2007 | EP1818029A2 Sequential drug delivery systems |
| 08/15/2007 | EP1818008A1 Noninvasive measurements of chemical substances |
| 08/15/2007 | EP1817941A2 Compositions exhibiting inhibition of cyclooxygenase-2 |
| 08/15/2007 | EP1817834A1 Method and installation means for installing an electrical machine |
| 08/15/2007 | EP1817415A2 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN AND INTERLEUKIN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/15/2007 | EP1817323A1 Tetrahydropyrane derivatives for use as antidiabetics |
| 08/15/2007 | EP1817317A1 Methods for preparing pimecrolimus |
| 08/15/2007 | EP1817316A1 Ascomycin crystalline forms and preparation thereof |
| 08/15/2007 | EP1817314A1 Non-hygroscopic and powdery amorphous pimecrolimus |
| 08/15/2007 | EP1817312A1 Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease |
| 08/15/2007 | EP1817311A2 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| 08/15/2007 | EP1817310A1 (spirocyclylamido) aminothiophene compounds as c-kit proto-oncogene inhibitors |
| 08/15/2007 | EP1817308A2 Cyclopamine analogues and methods of use thereof |
| 08/15/2007 | EP1817307A2 New pseudopolymorph of desloratadine formed with carbon dioxide |
| 08/15/2007 | EP1817306A1 Triazoles and their use as bradykinin b1 receptor antagonists |
| 08/15/2007 | EP1817303A2 Substituted pyridines with activity on syk kinase |
| 08/15/2007 | EP1817302A2 Piperidinyl piperidine tachykinin receptor antagonists |
| 08/15/2007 | EP1817301A1 Potentiators of glutamate receptors |
| 08/15/2007 | EP1817300A1 Potentiators of glutamate receptors |
| 08/15/2007 | EP1817297A1 Dibenzyl amine compounds and derivatives |
| 08/15/2007 | EP1817296A1 Potentiators of glutamate receptors |
| 08/15/2007 | EP1817295A1 Triazole compounds that modulate hsp90 activity |
| 08/15/2007 | EP1817294A1 1,2,3,4-tetrahydropyrazin-2-yl acetamides and their use as bradykinin antagonists for the treatment of inflammation related disorders |
| 08/15/2007 | EP1817291A1 4-hydroxybenzomorphans |
| 08/15/2007 | EP1817288A1 Dual antiplatelet/anticoagulant pyridoxine analogs |
| 08/15/2007 | EP1817287A1 Aromatic ether derivatives useful as thrombin inhibitors |
| 08/15/2007 | EP1817286A1 Donepezil salts suitable for the preparation of pharmaceutical compositions |
| 08/15/2007 | EP1817284A2 Cycloalkyl piperidine tachykinin receptor antagonists |
| 08/15/2007 | EP1817282A1 Phenoxyacetic acid derivatives useful for treating respiratory diseases |
| 08/15/2007 | EP1817281A1 N- [(3s)- pyrrolidin-3-yl]- benzamide derivatives as monoamine re-uptake inhibitors |
| 08/15/2007 | EP1817279A2 17,20(z)-dehydro vitamin d analogs and their uses |
| 08/15/2007 | EP1817278A2 2-methylene-18,19-dinor-1alfa-hydroxy-homopregnacalciferol and its uses |
| 08/15/2007 | EP1817276A1 Cathepsin cysteine protease inhibitors |
| 08/15/2007 | EP1817275A1 Haloalkyl containing compounds as cysteine protease inhibitors |
| 08/15/2007 | EP1817066A2 Medical device for delivering biologically active material |
| 08/15/2007 | EP1817057A1 Ptpase inhibitors and t-cell activators for treating cancer |
| 08/15/2007 | EP1817044A1 Composition comprising a polysaccharide with bacteria blocking action |
| 08/15/2007 | EP1817041A2 Tafi inhibitors and their use to treat pulmonary fibrosis |